MedTrace Logo

Drug Interaction Study Between AZD3480 and Warfarin

NCT00689637 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2009-07-02

No results posted yet for this study

Summary

The purpose of the study is to evaluate if AZD3480 and warfarin interact with each other or not, i.e. show the same or altered plasma concentration profiles when co-administered compared to administered alone.

Conditions

Interventions

DRUG

AZD3480

AZD3480 capsules qd, 12 days

DRUG

Placebo

Placebo capsules qd, 12 days

DRUG

Warfarin

Warfarin: single dose on day 6

Sponsors & Collaborators

Principal Investigators

  • Hans-Göran Hårdemark, MD · Clinical Neuroscience TA AstraZeneca R&D Södertälje, Sweden

  • Cyril Clarke, MD · ICON Development Solutions Manchester, UK

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-09-30
Completion
2009-02-28

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00689637 on ClinicalTrials.gov